Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine February 2019, 60 (2) 6A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Steven Larson.

Page 151

Molecularly targeted PCa surgery: Maurer and colleagues provide a brief overview of evidence and experience supporting the potential for prostate-specific membrane antigen–guided precision surgery in recurrent prostate cancer.

Page 156

First-in-human regulatory harmonization: Schwarz and colleagues offer an educational overview of regulatory and submission requirements governing investigational agents for first-in-human radiopharmaceuticals in Europe and North America.

Page 158

New developments in PRRT: Nicolas and colleagues summarize the current state of peptide-receptor radionuclide therapy, including β− and α particles and Auger electrons, and perspectives on near-term and future advances in treatment applications.

Page 167

131I and salivary glands in DTC: Selvakumar and colleagues quantitatively assess the long-term effects of 131I treatment on salivary gland function in survivors of pediatric differentiated thyroid cancer.

Page 172

Prognostic and whole-body MATV/TLG in mCRC: Woff and colleagues explore the prognostic value of baseline whole-body metabolically active tumor volume and total lesion glycolysis measured with 18F-FDG PET/CT in patients with chemorefractory metastatic colorectal cancer treated with multikinase inhibitors.

Page 178

68Ga-PSMA PET/CT in HCC: Kesler and colleagues evaluate the potential role of 68Ga–prostate-specific membrane antigen imaging in patients with hepatocellular carcinoma and compare it with 18F-FDG PET/CT results.

Page 185

SUR in trimodal treated esophageal cancer: Bütof and colleagues investigate the prognostic value of baseline PET parameters for results at the end of neoadjuvant radiochemotherapy and compare SUR metrics with conventional PET parameters for quantification of tumor metabolism.

Page 192

Radiomics in vulvar cancer: Collarino and colleagues research the question of whether radiomic features derived from preoperative 18F-FDG PET images can predict tumor biology and prognoses in women with invasive squamous cell carcinoma of the vulva.

Page 199

Tumor volume in Hodgkin lymphoma: Mettler and colleagues analyze the prognostic impact of metabolic tumor volume measurements obtained by different means in advanced-stage Hodgkin lymphoma patients treated as part of a larger clinical trial.

Page 207

Targeting HK2 in HK1–HK2+ tumors: Xu and colleagues use HK2 knockdown and knockout approaches to investigate the role of HK2 in cancer cell proliferation, in vivo xenograft tumor progression, and 18F-FDG tumor accumulation.

Page 212

PR PET and ER function: Paquette and Turcotte offer perspective on progesterone receptor–targeting PET tracers and estrogen receptor functionality in predicting response to endocrine therapies and preview an article in this issue of JNM on an estradiol challenge protocol.

Page 218

18F-FFNP uptake with estradiol challenge: Salem and colleagues evaluate the ability of this molecular imaging agent to measure alterations in progesterone receptor protein levels and isoform expression in response to 17β-estradiol challenge in human breast cancer cells and xenografts.

Page 220

PSMA PET/CT–based salvage radiotherapy: Schmidt-Hegemann and colleagues implement prostate-specific membrane antigen PET/CT-guided salvage radiotherapy in prostate cancer patients after radical prostatectomy and report on effects on biochemical recurrence–free survival.

Page 227

68Ga-PSMA-11 PET/CT and RT management: Koerber and colleagues analyze the impact of 68Ga-labeled prostate-specific membrane antigen-HBED-CC PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer.

Page 234

18F-ASEM PET in recent-onset psychosis: Coughlin and colleagues use PET imaging to compare hippocampal binding of this α7-nicotinic acetylcholine receptor tracer in individuals with recent-onset psychosis and in healthy controls.

Page 241

18F-GP1 PET for thromboembolism: Kim and colleagues explore the detection rate of thromboembolic foci with 18F-glycoprotein 1 PET/CT in patients with acute venous thromboembolism and evaluate the agent’s safety, biodistribution, pharmacokinetics, and metabolism.

Page 244

Tumor control probability of micrometastases: Falzone and colleagues investigate the effect of heterogeneous radionuclide distribution on tumor control probability in a micrometastasis model in 3 different cell lines.

Page 250

GluN2B imaging by PET: Haider and colleagues describe development of a promising radiofluorinated probe that exhibits specificity and selectivity for the GluN2B-containing N-methyl-d-aspartate complex and detail in vivo target occupancy studies in rodents.

Page 259

18F-NaF PET and intracranial calcification: Al-Zaghal and colleagues determine the role of 18F-sodium fluoride PET/CT imaging in assessment of physiologic molecular calcification in intracranial structures and discuss implications for research in age-related neurodegenerative processes.

Page 267

MR-assisted PET data optimization: Chen and colleagues propose an efficient MR-assisted PET data optimization method for attenuation correction, PET motion correction, and anatomy-aided reconstruction.

Page 272

Elastic motion correction in PET/CT: Meier and colleagues evaluate in phantom and patient studies a recently developed elastic motion deblurring technique that makes use of all acquired PET data and compare its performance with more conventional techniques.

Page 279

Normalization of 18F-flutemetamol PET: Lilja and colleagues introduce a method to spatially normalize 18F-flutemetamol images using a synthetic template based on principal-component images to overcome the challenges of different uptake patterns in Aβ-positive and -negative subjects.

Page 285

  • © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (2)
Journal of Nuclear Medicine
Vol. 60, Issue 2
February 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Feb 2019, 60 (2) 6A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Feb 2019, 60 (2) 6A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
  • Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer
  • 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients
  • Measuring Estrogen Receptor Functionality Using Progesterone Receptor PET Imaging: Rising to the (Estradiol) Challenge!
  • Sensitivity and Isoform Specificity of 18F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer
  • Use of 18F-ASEM PET to Determine the Availability of the α7-Nicotinic Acetylcholine Receptor in Recent-Onset Psychosis
  • New Developments in Peptide Receptor Radionuclide Therapy
  • Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin
  • Discussions with Leaders: A Conversation Between Steven Larson and Johannes Czernin
  • Glycoprotein IIb/IIIa Receptor Imaging with 18F-GP1 PET for Acute Venous Thromboembolism: An Open-Label, Nonrandomized, Phase 1 Study
  • Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor
  • Spatial Normalization of 18F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
  • Evaluation of a Novel Elastic Respiratory Motion Correction Algorithm on Quantification and Image Quality in Abdominothoracic PET/CT
  • Outcome After PSMA PET/CT–Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis
  • Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible?
  • Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer
  • 68Ga-Labeled Prostate-Specific Membrane Antigen Is a Novel PET/CT Tracer for Imaging of Hepatocellular Carcinoma: A Prospective Pilot Study
  • Radiomics in Vulvar Cancer: First Clinical Experience Using 18F-FDG PET/CT Images
  • An Efficient Approach to Perform MR-Assisted PET Data Optimization in Simultaneous PET/MR Neuroimaging Studies
  • Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma
  • Prognostic Value of Standardized Uptake Ratio in Patients with Trimodality Treatment of Locally Advanced Esophageal Carcinoma
  • Targeting Micrometastases: The Effect of Heterogeneous Radionuclide Distribution on Tumor Control Probability
  • Assessment of Physiologic Intracranial Calcification in Healthy Adults Using 18F-NaF PET/CT
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire